Literature DB >> 22894671

Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease.

Jorge J Nieva1, Peter Kuhn.   

Abstract

Cancer is currently diagnosed and treated based on the results of a tissue biopsy of the primary tumor or a metastasis using invasive techniques such as surgical resection or needle biopsy. New technology for retrieving cancer cells from the circulation, developed in the last 5 years, has made it possible to obtain a 'fluid biopsy' from the bloodstream without the need for an invasive procedure. This technological development makes it possible to diagnose and manage cancer from a blood test rather than from a traditional biopsy. It also allows the repeated sampling of cancer cells from a patient, making it possible, in a practical manner, to interrogate the disease repeatedly in order to understand the mechanisms by which cancer cells evolve within a given individual. The ability to obtain cancer cells repeatedly also has the potential to substantially advance drug development by enabling early ex vivo validation of both targets and early-stage compounds, as well as creating new efficiencies in the drug development process during clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22894671      PMCID: PMC3658625          DOI: 10.2217/fon.12.91

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  59 in total

1.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Authors:  H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Authors:  A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Authors:  Sai-Hong Ignatius Ou; Lyudmila Bazhenova; D Ross Camidge; Benjamin J Solomon; June Herman; Tatiana Kain; Yung-Jue Bang; Eunice L Kwak; Alice T Shaw; Ravi Salgia; Robert G Maki; Jeffrey W Clark; Keith D Wilner; A John Iafrate
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

4.  Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Authors:  Marco Wendel; Lyudmila Bazhenova; Rogier Boshuizen; Anand Kolatkar; Meghana Honnatti; Edward H Cho; Dena Marrinucci; Ajay Sandhu; Anthony Perricone; Patricia Thistlethwaite; Kelly Bethel; Jorge Nieva; Michel van den Heuvel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

5.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 6.  Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.

Authors:  Patrick C Ma; Lawrence Blaszkowsky; Ajit Bharti; Andras Ladanyi; Stine-Kathrein Kraeft; Adam Bruno; Arthur T Skarin; Lan Bo Chen; Ravi Salgia
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

7.  Circulating tumor cells predict survival in patients with metastatic prostate cancer.

Authors:  Jose G Moreno; M Craig Miller; Steve Gross; W Jeffrey Allard; Leonard G Gomella; Leon W M M Terstappen
Journal:  Urology       Date:  2005-04       Impact factor: 2.649

8.  Cell analysis system based on immunomagnetic cell selection and alignment followed by immunofluorescent analysis using compact disk technologies.

Authors:  A G Tibbe; B G de Grooth; J Greve; P A Liberti; G J Dolan; L W Terstappen
Journal:  Cytometry       Date:  2001-01-01

9.  Detection and characterization of carcinoma cells in the blood.

Authors:  E Racila; D Euhus; A J Weiss; C Rao; J McConnell; L W Terstappen; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

10.  Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Authors:  Matthew G Krebs; Jian-Mei Hou; Robert Sloane; Lee Lancashire; Lynsey Priest; Daisuke Nonaka; Tim H Ward; Alison Backen; Glen Clack; Andrew Hughes; Malcolm Ranson; Fiona H Blackhall; Caroline Dive
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

View more
  5 in total

Review 1.  Circulating tumor cell enrichment based on physical properties.

Authors:  Ramdane A Harouaka; Merisa Nisic; Si-Yang Zheng
Journal:  J Lab Autom       Date:  2013-07-05

2.  Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.

Authors:  Wujun Zhao; Yang Liu; Brittany D Jenkins; Rui Cheng; Bryana N Harris; Weizhong Zhang; Jin Xie; Jonathan R Murrow; Jamie Hodgson; Mary Egan; Ana Bankey; Petros G Nikolinakos; Haythem Y Ali; Kristina Meichner; Lisa A Newman; Melissa B Davis; Leidong Mao
Journal:  Lab Chip       Date:  2019-05-14       Impact factor: 6.799

Review 3.  Biophysical technologies for understanding circulating tumor cell biology and metastasis.

Authors:  Derrick W Su; Jorge Nieva
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 4.  Clinical Application of Circulating Tumor Cells in Gastric Cancer.

Authors:  Moon Won Lee; Gwang Ha Kim; Hye Kyung Jeon; Su Jin Park
Journal:  Gut Liver       Date:  2019-02-27       Impact factor: 4.519

5.  Tandem microfluidic chip isolation of prostate and breast cancer cells from simulated liquid biopsies using CD71 as an affinity ligand.

Authors:  Bhagya Wickramaratne; Dimitri Pappas
Journal:  RSC Adv       Date:  2020-09-02       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.